177 related articles for article (PubMed ID: 29862545)
1. Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?
Eşkazan AE
Br J Clin Pharmacol; 2018 Aug; 84(8):1635-1638. PubMed ID: 29862545
[No Abstract] [Full Text] [Related]
2. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
3. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
Breccia M; Foà R
Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
[TBL] [Abstract][Full Text] [Related]
4. Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
McMullan RR; McConville C; McMullin MF
Ulster Med J; 2019 May; 88(2):105-110. PubMed ID: 31061559
[TBL] [Abstract][Full Text] [Related]
5. The concept of treatment-free remission in chronic myeloid leukemia.
Saußele S; Richter J; Hochhaus A; Mahon FX
Leukemia; 2016 Aug; 30(8):1638-47. PubMed ID: 27133824
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression.
Rivano M; Cancanelli L; Zovi A; Addis C; Mengato D; Chiumente M; Messori A
J Chemother; 2020 Sep; 32(5):268-271. PubMed ID: 31984876
[No Abstract] [Full Text] [Related]
7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
8. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
9. Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia.
Alfayez M; Richard-Carpentier G; Jabbour E; Vishnu P; Naqvi K; Sasaki K; Cortes J; Pemmaraju N
Br J Haematol; 2019 Nov; 187(4):543-545. PubMed ID: 31584727
[No Abstract] [Full Text] [Related]
10. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Rea D; Ame S; Berger M; Cayuela JM; Charbonnier A; Coiteux V; Cony-Makhoul P; Dubruille V; Dulucq S; Etienne G; Legros L; Nicolini F; Roche-Lestienne C; Escoffre-Barbe M; Gardembas M; Guerci-Bresler A; Johnson-Ansah H; Rigal-Huguet F; Rousselot P; Mahon FX;
Cancer; 2018 Jul; 124(14):2956-2963. PubMed ID: 29723417
[TBL] [Abstract][Full Text] [Related]
11. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
Mahon FX; Etienne G
Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
[TBL] [Abstract][Full Text] [Related]
12. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
13. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
Kimura S; Imagawa J; Murai K; Hino M; Kitawaki T; Okada M; Tanaka H; Shindo M; Kumagai T; Ikezoe T; Uoshima N; Sato T; Watanabe R; Kowata S; Hayakawa M; Hosoki T; Ikeda K; Kobayashi T; Kakinoki Y; Nishimoto T; Takezako N; Shibayama H; Takaori-Kondo A; Nakamae H; Kawaguchi A; Ureshino H; Sakamoto J; Ishida Y;
Lancet Haematol; 2020 Mar; 7(3):e218-e225. PubMed ID: 31978329
[TBL] [Abstract][Full Text] [Related]
14. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
17. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
[TBL] [Abstract][Full Text] [Related]
18. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
Shah NP
J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
[TBL] [Abstract][Full Text] [Related]
19. Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response.
Astrugue C; Bénard A; Bosco-Levy P; Dulucq S; Rouyer M; Lassalle R; Hayes N; Mahon FX
Value Health; 2021 May; 24(5):683-690. PubMed ID: 33933237
[TBL] [Abstract][Full Text] [Related]
20. Treatment-free remission in patients with chronic myeloid leukaemia.
Ross DM; Hughes TP
Nat Rev Clin Oncol; 2020 Aug; 17(8):493-503. PubMed ID: 32377005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]